AMGN vs. GILD, MRNA, PFE, ISRG, ABT, SYK, SNY, ELV, NVS, and MDT
Should you be buying Amgen stock or one of its competitors? The main competitors of Amgen include Gilead Sciences (GILD), Moderna (MRNA), Pfizer (PFE), Intuitive Surgical (ISRG), Abbott Laboratories (ABT), Stryker (SYK), Sanofi (SNY), Elevance Health (ELV), Novartis (NVS), and Medtronic (MDT). These companies are all part of the "medical" sector.
Amgen (NASDAQ:AMGN) and Gilead Sciences (NASDAQ:GILD) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, community ranking, risk and dividends.
Amgen pays an annual dividend of $9.00 per share and has a dividend yield of 2.9%. Gilead Sciences pays an annual dividend of $3.08 per share and has a dividend yield of 4.7%. Amgen pays out 128.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Gilead Sciences pays out 855.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.
Amgen currently has a consensus target price of $305.05, indicating a potential downside of 0.74%. Gilead Sciences has a consensus target price of $83.69, indicating a potential upside of 28.91%. Given Gilead Sciences' higher possible upside, analysts clearly believe Gilead Sciences is more favorable than Amgen.
Amgen has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.22, meaning that its share price is 78% less volatile than the S&P 500.
Amgen has a net margin of 12.74% compared to Gilead Sciences' net margin of 1.76%. Amgen's return on equity of 156.21% beat Gilead Sciences' return on equity.
Amgen has higher revenue and earnings than Gilead Sciences. Amgen is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.
76.5% of Amgen shares are owned by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are owned by institutional investors. 0.7% of Amgen shares are owned by insiders. Comparatively, 0.3% of Gilead Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Gilead Sciences received 923 more outperform votes than Amgen when rated by MarketBeat users. Likewise, 77.37% of users gave Gilead Sciences an outperform vote while only 72.45% of users gave Amgen an outperform vote.
In the previous week, Amgen had 76 more articles in the media than Gilead Sciences. MarketBeat recorded 92 mentions for Amgen and 16 mentions for Gilead Sciences. Gilead Sciences' average media sentiment score of 0.68 beat Amgen's score of 0.49 indicating that Gilead Sciences is being referred to more favorably in the news media.
Summary
Amgen beats Gilead Sciences on 13 of the 20 factors compared between the two stocks.
Get Amgen News Delivered to You Automatically
Sign up to receive the latest news and ratings for AMGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AMGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
